S100B and infection: A clinical trial to test the safety and feasibility of minocycline in acute TBI found that treatment had no impact on serum levels of S100 calcium binding protein B (S100-B), a well-established TBI biomarker, and no infections were recorded in liver function tests up to 12 months post-treatment, thus concluding that minocycline is safe for patients suffering from TBI (91) (NCT01058395).